A B S T R A C T A protein with the electrophoretic, immunologic, and hormone-binding properties of thyroxinebinding globulin (TBG) has been prepared from human plasma and labeled with radioiodine (1"6I) by an enzymatic method of iodination. The ['I]TBG retained the electrophoretic and immunologic characteristics of unlabeled TBG but exhibited a partial loss of thyroxinebinding activity, as assessed by affinity chromatography. The in vivo behavior of ['I]TBG was studied in six euthyroid subjects (controls) with normal serum levels of TBG as measured both by radioimmunoassay and by determination of maximal TR-binding capacity and in four male patients with untreated primary hyperthyroidism, three of whom had elevated serum TBG. The half-time of the final slope of the plasma disappearance curve averaged 5.0 days +1.2 (SD) in the controls and ranged from 3.9 to 10.9 days in the hypothyroid patients. The distribution volume was similar in the two groups, 6.7±1.3 vs. 7.1±2.1 liters. The catabolic clearance rate averaged 0.99±0.33 liters plasma/24 h in the controls and 0.92±0.46 in the hypothyroids. The absolute turnover rate of TBG, calculated from the catabolic clearance rate multiplied by the serum concentration of radioimmunoassayable TBG, averaged 17.8±2.1 mg/day in the controls and ranged from 14.8 to 33.2 mg/day in the hypothyroids. Among the entire group of subjects there was no correlation between the serum TBG concentration and the absolute turnover rate of TBG.
INTRODUCTION
Thyroxine-binding globulin (TBG),' the major extracellular thyroid hormone-binding protein in man, has been isolated and studied by several groups (2) (3) (4) (5) (6) (7) . It is a glycoprotein with a single binding site for thyroxine. Most workers place its molecular weight at about 60,000. The plasma concentration of TBG, measured by maximal T4-binding capacity (8) or by radioimmunoassay (9) , varies over a wide range depending upon genetic and environmental factors. As is true for all plasma proteins, the level of TBG in the plasma is determined by the relative rates of synthesis and removal and by the distribution of the protein between intravascular and extravascular compartments.
The present study was undertaken in order to define the in vivo distribution and metabolism of TBG in humans. This report describes a method of preparing TBG from human plasma and of labeling the protein with radioiodine. Some of the chemical and immunologic properties of the labeled TBG will be presented as well as the in vivo behavior of this tracer in human subjects. While this investigation was in progress, Refetoff, Fang, Robin, and Marshall published findings of a similar study in abstract form (10) .
METHODS

Materials
The starting material for the purification of TBG was blood bank plasma, collected from volunteer donors and stored in acid-citrate-dextrose at 4°C. Sepharose 2B and Sephadex G-75 and G-25, were obtained from Pharmacia Fine Chemicals, Inc., Piscataway, N. J. Cyanogen bromide was obtained from Eastman Organic Chemicals Div., Eastman Kodak Co., Rochester, N. Y., and used only from newly opened bottles. 3,5,3'-Triiodo-L-thyronine (T3) and L-thyroxine (T4), both in the form of the sodium salt, were supplied by Sigma Chemical Co., St. Louis, Mo. Acrylamide and bisacrylamide (N,N'-methylene bisacrylamide) were obtained from Bio-Rad Laboratories, Richmond, Calif., tetramethylethylenediamine was from Eastman Organic Chemicals Div., and ammonium persulfate was from Mallinckrodt Chemical Works, St. Louis, Mo. Lactoperoxidase was obtained from Calbiochem, La Jolla, Calif. Other chemicals used were reagent-grade and purchased from commercial suppliers. ['251 ]iodide (for iodination) was obtained in carrier-free form from New England Nuclear, Boston, Mass.
3'I-labeled T4 (sp act ACi/,ag) and "3'I-labeled T3 (sp act ,uCi/,ug) were obtained from Amersham/ Searle Corp., Arlington Heights, Ill.
Purification of TBG
Preparation of Ts-substituted Sepharose. The method described by Pensky and Marshall (11) for the preparation of T4-substituted Sepharose was modified as follows: T3, 100 mg, labeled with approximately 10 ,tCi [.31 .]T3 and dissolved in 5 ml 0.1 M KOH, was added to 100 ml cyanogen bromide-activated Sepharose 2B. The mixture was stirred gently for 16 h at 4°C. Unreacted T3 was removed by washing the settled Sepharose with 100 vol of 0. con Corp., Scientific Sys. Div., Lexington, Mass.). Aliquots were removed for determination of total protein by the method of Lowry, Rosebrough, Farr, and Randall (13) and for analysis by disk electrophoresis by the method of Davis (14) .
Jodination of TBG
To approximately 300 ,ug purified TBG, in 0.05 M sodium phosphate buffer, pH 7.4, were added 6 pg lactoperoxidase and 5 mCi [l2I]iodide, all in a total volume of 0.5 ml. The iodination reaction, which was carried out at room temperature, was initiated and maintained by two additions, 20 ng each, of H202 at intervals of 60 s. 60 s after the second addition of H202 the reaction was stopped with sodium metabisulfite. Unreacted iodide was separated from protein on a 1 X 12-cm column of Sephadex G-75 medium grade that had previously been washed with 1%o human serum albumin (HSA) in 0.05 M sodium phosphate buffer, pH 7.4. The iodination yield ranged from 20 to 40%. 
Antibody preparation
Two 2-kg male New Zealand albino rabbits were immunized with 200-400 ,g purified TBG, emulsified in 1 ml complete Freund's adjuvant. Inoculation was done in 15-20 sites over the back of each animal at intervals of 2-3 wk for a total of four inoculations. One rabbit was given a final "booster" immunization of 700 ,g partially purified TBG (affinity-column eluate). Blood was collected at 10-14 days after each inoculation. The titer of the rabbit antisera was determined from the dilution of antiserum that caused precipitation of 50% of added ['5I]TBG (in a minimal tracer amount) with either polyethylene glycol or antirabbit goat serum used to precipitate the immune complex. Immunoelectrophoresis was performed according to the method of Scheidegger (15) .
Radioimmunoassay of serum TBG
The assay was carried out in 0.05 M sodium phosphate buffer, pH 7.4, containing 0.1% normal rabbit serum, rabbit antiserum against human TBG, produced as described above, in a final dilution of 1: 72,000, ["25I]TBG (1-2 ng TBG protein), and a diluted sample of test serum, equivalent to 0.5-1 Al of undiluted serum. After incubation of the above mixture for 48 h at 4°C, a second antibody (goat antirabbit serum) was added. After an additional 24 h, the immune precipitate was separated by centrifugation and assayed for "I. A standarfd curve was constructed with each assay by using a pool of normal sera as a reference standard. The concentration of TBG in this serum pool was determined to be 1.82 mg/100 ml by using highly purified TBG as a primary standard. The results in patients' sera were expressed in mg TBG/100 ml by referring to this serum pool. All samples were run in triplicate. The minimum concentration of TBG detectable by this assay is 1.0 ng TBG (0.067 A1l serum). The specificity of the assay for TBG was established by finding no Determination of T4-binding capacity of purified TBG Small columns, fashioned from 1 ml tuberculin syringes, were filled with Sephadex, G-25 fine grade, to a bed-volume of 0.7 ml. These were equilibrated with 0.1 M Tris-glycinate buffer, pH 8.3. To solutions of a known concentration of purified TBG and a tracer quantity of [..lI]T4 in the same buffer were added various known amounts of unlabeled L-T4. After equilibration of these mixtures for 30 min at room temperature, 50 I-L of each was applied to a Sephadex column and allowed to enter the gel. The protein (TBG) was eluted from the column with 1.5 ml Tris-glycinate buffer. The proportion of ["'I] T4 eluted with protein was determined and used to calculate the amount of total T4 bound to TBG. The maximal T,-binding capacity of TBG was computed from the maximal amount of T4 bound per unit quantity of TBG protein.
Patients
There were six subj ects in the control group. All were eumetabolic by clinical assessment, had normal levels of serum T4 and free T4 index, and normal serum TBG T4-binding capacity. One patient in this group (E. L.) had undergone a total thyroidectomy 20 yr previously and had been taking L-T4, 0.2 mg/day, continuously since his operation. The other five subjects had no thyroid disease.
Four patients with primary thyroid failure were studied. All exhibited clinical features of hypothyroidism in varying degrees, had low levels of serum T4 and free T4 index and elevated serum thyroid-stimulating hormone (radioimmunoassay). Serum TBG T4-binding capacity was above the normal range in three members of this group.
In vivo kinetics studies ["JI]TBG, from 5 to 15 AGCi (1-3 /ig TBG protein), in 0.1% HSA, was sterilized by Millipore filtration immediately before intravenous administration to each subj ect. Samples of blood were collected at 30 min and 4, 6, and 24 h postdose and at 24-h intervals thereafter for a period of 10-14 days. Complete 24-h collections of urine were made for the same period. Each subj ect received saturated solutions of potassium iodide, five drops twice daily for the duration of the study. Plasma samples were assayed for total "'I concentration, trichloroacetic acid-precipitable "25I (PB 'MI), and ethanol-insoluble '9. Aliquots of the injected dose, diluted in normal human plasma, were subjected to the above procedure.
Analysis of kinetics data
After an initial phase of 2 or 3 days, the plasma disappearance curve of PB 125I approximated a single exponential slope from which a fractional turnover rate, k, was calculated (k = ln 2/tD). The daily urinary excretion of 'A serum sample from one of these individuals was generously supplied by Dr. Samuel Refetoff, who found no immunoreactive TBG as well as no T4-binding activity by the alpha-globulins of this patient's serum (16) . I, from day 3 to the end of each study, declined in parallel with the plasma PB "I5J concentration. A catabolic clearance rate, in liters plasma per day, was calculated, for each 24-h interval after day 2, from the urinary 'I divided by the mean plasma PB "'I concentration during that interval. The clearance rate, so calculated, was reasonably constant during the study in each case. The total distribution volume of ['2I]TBG was computed from the mean clearance rate (liters/day) divided by the fractional turnover rate, k (days-'). This method of analysis assumes that the final plasma PB "'I slope accurately reflects the turnover rate of the TBG pool and that isotopic equilibrium is achieved during the initial 2-3 days postinjection. Furthermore, fecal (nonurinary) losses of tracer and tracee are neglected. The absolute turnover rate was calculated as the product of the serum TBG concentration (determined by radioimmunoassay) and the catabolic clearance rate.
Other procedures
Total serum T4 was measured by a competitive-binding technique (17) . Serum free T4 index was determined as the product of total T4 times the uptake of labeled T4 by Sephadex, both values expressed as a percentage of the value obtained in a pool of normal sera (18) . The maximal T4-binding capacity of serum TBG was determined by using reverse-flow paper electrophoresis in ammonium carbonate buffer, pH 8.4, according to Robbins (8) .
RESULTS Purification of TBG. The protein eluted from the affinity columns included albumin, globulins, and a component with the electrophoretic mobility of TBG ( 0.85 mol of T4 are bound per mole of TBG. Upon gel filtration of purified TBG labeled with [mI]T4 on a Bio-Gel P-60 column the protein appeared at an elution volume identical to that of HSA, indicating a similar molecular size of the two proteins. As further evidence of purity of the final TBG product, Ouchterlony doublediffusion analysis of purified TBG exhibited a single precipitin line against rabbit antiserum to TBG and no visible precipitation against either a highly potent antiserum to HSA or an antiserum to whole serum (Fig. 3). (Presumably, the latter antiserum contained too low a titer of antibodies against TBG to give a visible precipitin line.)
Characterization of [ (Fig. 4) After a brief wash with the buffer to remove loosely bound serum proteins, the proportion of total 'I that was retained on the column was determined. (This was taken to be a measure of the T4-binding activity of the ['I]TBG.) As shown in Table I, retention, a finding consistent with the relatively low affinity of albumin for T4.
In separate experiments, the efficiency of the T4-Sepharose columns in retaining native unlabeled TBG was tested as follows: 2 ml of normal serum was applied to a column, and the unadsorbed proteins were eluted in an identical fashion to that used in analysis of [5I]TBG preparations. The maximal T4-binding capacity of TBG in aliquots of the normal serum was measured by reverse-flow electrophoresis before and after exposure to the affinity column. (Suitable corrections were made for dilution on the column.) An average of 72% of the TBG binding capacity was removed by the column. These findings indicate that the affinity column retained about twice as much unlabeled TBG as [5I]-TBG. The apparent loss in T4-binding activity by radioiodinated TBG could be a consequence of a decrease in L. H., who had the highest T4 binding capacity, showed the highest TBG by immunoassay. Among the controls, however, the correlation was less perfect, for which we have no explanation.
In vivo metabolism. Fig. 6 shows the time-course of plasma PB 'I concentration and the daily urinary excretion of 'I after injection of [1'"I]TBG in a control subject. Nearly 30% of the injected dose appeared in the urine during the initial 48 h. Thereafter, the rate of excretion paralleled the plasma disappearance of PB "'I. Presumably, the "excessive" urinary excretion of "I in the initial 2 days was a result of the relatively rapid clearance from the plasma of damaged or denatured ['"JI]TBG. This phenomenon was observed to a variable degree in every subject (Table II) . The plasma disappearance curves for all studies are illustrated in Fig. 7 . In every case a single exponential slope was obtained from day 3 onward. The time-zero intercept of the final exponential varied from one study to another, depending largely upon the ["I]TBG preparation administered.
The values obtained for various parameters of ['I]-TBG kinetics are given in Table II . Among the control subjects, the half-time of the final slope of the plasma disappearance curve ranged from 3.61 to 6.64 days (mean = 5.01), the catabolic clearance rate ranged from 0.634 to 1.61 liters/day (mean = 0.989), and the volume of distribution, from 4.86 to 8.59 liters (mean = 6.68).
The absolute rate of turnover of TBG ranged from 14.8 to 20.3 mg/day (mean = 17.8+2.1 mg/day).
Among the hypothyroid subjects as a group, there was no significant difference from the controls in any of the parameters of TBG turnover. However, two of these patients (J. R. and L. H.) exhibited catabolic clearance rates below the normal range. In patient L. H.
this was due to a prolonged t3, more than twice the normal mean, while in the other case (J. R.) a small distribution volume was responsible. The values for the absolute rate of TBG turnover in both of these subjects Refetoff, Fang, and Marshall (22) by Marshall and Pensky in their preparations of TBG have reported that the introduction of up to six atoms purified by affinity chromatography (20) .
of iodine per molecule of human TBG, using the chlora-
The iodinated preparations of TBG showed no evi-mine-T method, did not shorten the survival of the ladence of alteration from native TBG in terms of the beled protein in the circulation of rabbits, compared to electrophoretic mobility in polyacrylamide gel or in im-TBG labeled with one atom per molecule. munologic reactivity. In another respect, however, there sented in Table I By the method used to analyze the kinetics data, the catabolic clearance rate and the volume of distribution are not influenced by variations from one lot to another in the proportion of rapidly cleared tracer, i.e., that fraction of injected label which appeared in the urine within the initial 48 h. In fact, the catabolic clearance rate did not correlate with the percentage of "early" cleared tracer (Table II) . Therefore, it would seem reasonably justified to accept the results at least as a first approximation of the kinetic behavior of TBG in man.
Thyroxine-binding prealbumin (TBPA) is generally accepted to be of lesser importance than TBG in the transport of T4; this protein binds a smaller proportion of circulating T4 than does TBG (23 patients with thyroid dysfunction. Decreased TBG has been described in thyrotoxicosis (28, 29) . TBG maximal T4-binding capacity is increased above normal to a variable degree in a large proportion of patients with hypothyroidism (29) (30) (31) (32) . We anticipated finding a slower than normal removal rate of injected labeled TBG in hypothyroidism, but only one of the four patients in this category showed a significant prolongation of the ti. In this patient (L. H.) a low catabolic clearance rate was counterbalanced by a high serum TBG concentration, so that the absolute turnover rate was normal. In none of the hypothyroid cases studied was the TBG turnover rate (presumably equal to production rate) reduced below the control range. Moreover, for all of the subjects in this study, there was no correlation between the serum TBG level and the absolute turnover rate. Because of the wide range of values for the kinetics parameters obtained in this small group of hypothyroid cases, no conclusions can be drawn regarding the pathogenetic mechanism of the elevated serum TBG level found so often in this condition. Studies of albumin kinetics in hypothyroid patients have shown a decrease in fractional removal rate (33, 34) which is reversed toward normal after treatment with thyroid hormone (34) . In contrast to our findings, albumin synthesis is reduced as well in hypothyroidism; the serum level of albumin is either normal or subnormal in this condition. This differs from the case of TBG; elevations in TBG are commonly found in hypothyroidism as noted above.
The mechanisms by which TBG and other plasma glycoproteins are cleared from the circulation are not understood, but available evidence (summarized in reference 35) indicates that enzymatic removal of one or more residues of sialic acid may be an initial step in the normal catabolic process. The liver has been implicated as an important site of uptake of desialylated glycoproteins and may also be the organ where desialylation occurs (35) . In fact, a partially desialylated TBG has been detected in some patients with severe hepatocellular damage (36) . The question arises, whether the hypothyroid patient (L. H.) who exhibited an abnormally slow catabolic clearance of TBG suffered from a specific defect in one or another of the steps of TBG degradation. Our patient had no clinical or laboratory evidence of hepatic disease. Unfortunately, it was not possible to repeat the TBG turnover study after he had been rendered eumetabolic.
